drugset / Trial / NCT00202579

Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure

NCT00202579

Phase 2 Completed 12 enrolled Servier
Non-randomizedSingle-groupOpen-label

Summary

To evaluate the effects on heart function of ivabradine administered to patients with severe chronic heart failure

Timeline

Start
2004-09
Primary completion
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivabradine Small molecule 0.1 mg/kg Intravenous